3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
4
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
58
Small Cell Lung Carcinoma
22
Carcinoma, Hepatocellular
17
Neoplasms
15
Lung Neoplasms
14
Biliary Tract Neoplasms
12
Neoplasm Metastasis
11
Breast Neoplasms
11
Recurrence
10
Squamous Cell Carcinoma of Head and Neck
9
Melanoma
9
Carcinoma
9
Advanced Solid Tumors
8
Triple Negative Breast Neoplasms
7
Stomach Neoplasms
7
Lymphoma, Large B-Cell, Diffuse
7
Liver Neoplasms
7
Head and Neck Neoplasms
7
Urinary Bladder Neoplasms
6
Ovarian Neoplasms
6
Carcinoma, Renal Cell
6
Prostatic Neoplasms
5
Lymphoma
5
Uterine Cervical Neoplasms
4
Neoplasms by Site
4
Multiple Myeloma
4
Lymphoma, Follicular
4
Colorectal Neoplasms
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Pancreatic Neoplasms
3
Interventions
Gemcitabine
11
Cisplatin
10
pembrolizumab
7
Fluorouracil
3
Drug Therapy
3
spartalizumab
2
derazantinib
2
Leucovorin
2
trametinib
1
tislelizumab
1
silmitasertib
1
seribantumab
1
pertuzumab
1
olutasidenib
1
galactomannan
1
exatecan
1
durvalumab
1
becatecarin
1
Tegafur
1
Standard of Care
1
S 1 (combination)
1
Ritonavir
1
Quality of Life
1
Patient Reported Outcome Measures
1
Oxaliplatin
1
Observation
1
Nivolumab
1
Molecular Diagnostic Techniques
1
Microscopy, Confocal
1
Melphalan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Bile Duct Neoplasms
×
durvalumab
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts